Bidding war on: Valeant Pharmaceuticals (VRX) increases its offer for Obagi Medical (OMPI) to $24 a share in cash, a day after Merz Pharmaceuticals proposed $22. That bid had trumped Valeant's original offer of $19.75. Obagi has accepted Valeant's new proposal, which has sent the former's shares up 8.4% to $24.80.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Investor's Business Daily (Wed, 8:02AM)
at Benzinga.com (Tue, 4:00PM)
at Investor's Business Daily (Mon, 6:51PM)
Valeant CEO Explains Why The Company Is Acquiring Salix For $10.1 Billion Cash Instead Of An Equity Offeringat Benzinga.com (Mon, 2:27PM)
at Investor's Business Daily (Mon, 12:41PM)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs